News
05-06-2020, 08:34 AM
Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
More... (https://www.news-medical.net/news/20200506/Immune-checkpoint-inhibition-led-to-clinical-responses-in-patients-with-advanced-melanoma.aspx)
More... (https://www.news-medical.net/news/20200506/Immune-checkpoint-inhibition-led-to-clinical-responses-in-patients-with-advanced-melanoma.aspx)